Medtrum spotlights real-world AID use at Hong Kong diabetes meeting

Medtrum used EDM HK 2026 in Hong Kong to showcase its continuous glucose monitoring, tubeless insulin pumps and automated insulin delivery systems, while highlighting a local clinician’s experience with real-world use. The event underscored growing interest in easier-to-use diabetes technology and the need for ongoing patient support.

Why it matters: - Medtrum positioned its diabetes technology as a practical option for people who need tighter glucose control without adding more daily burden. - The Hong Kong meeting showed how automated insulin delivery can move from a technical concept to a day-to-day care tool for patients and clinicians. - The discussion also highlighted the importance of follow-up support after patients start using a closed-loop system.

What happened: - Medtrum joined healthcare professionals, partners and people living with diabetes at EDM HK 2026 in Hong Kong. - The 9th Annual Meeting of Endocrinology, Diabetes & Metabolism Hong Kong took place on 24-25 October. - Visitors stopped by the Medtrum booth to learn about continuous glucose monitoring, tubeless insulin pumps and automated insulin delivery systems. - The company also used the booth conversations to hear from doctors, nurses and other diabetes-care professionals in Hong Kong about their daily needs. - A symposium featured Dr. Chun-Yip Yeung, who presented “Hybrid Closed-loop Insulin Pump: Case Sharing from an Endocrinologist with Limited Pump Experience.”

The details: - Dr. Yeung said his earlier experience with insulin pumps was limited and few of his patients used them. - He said his patient population has become more varied, with more older adults developing insulin dependence later in life and often managing other medical conditions. - Dr. Yeung said repeated injections, carbohydrate counting and a more demanding routine can add to the burden of diabetes management. - He described the Medtrum AID system as relatively straightforward to set up compared with his previous experience. - In his practice, setup includes teaching patients and caregivers how to use the pump, change the reservoir and use the app. - The clinician enters treatment settings such as insulin requirements and glucose targets before automated insulin delivery is introduced. - One case involved a patient who became reluctant to leave home after starting multiple daily injections, despite previously enjoying lunches with friends and family. - Another case involved a patient who stayed active after starting pump therapy and continued playing golf. - Dr. Yeung said advances in insulin pumps and CGM can improve glucose control, safety and quality of life. - He described Medtrum’s tubeless AID system as effective, safe and affordable. - During the Q&A, Dr. Yeung said patients receive individual follow-up through Medtrum’s support network in Hong Kong, with dedicated communication channels available when needed.

Between the lines: - The event framed diabetes technology as more than hardware, with workflow, education and follow-up presented as part of the care model. - The cases shared at the symposium suggested that device choice can affect mobility, social life and confidence, not just blood sugar numbers. - Medtrum’s focus on local clinical feedback suggests the company is trying to show fit with everyday practice in Hong Kong, not just product capability.

What’s next: - Medtrum plans additional educational activities and workshops in Hong Kong. - Those sessions are expected to give healthcare professionals and the local diabetes community more chances to evaluate diabetes technology in practical settings. - Medtrum will continue promoting its CGM, tubeless patch pump and AID systems in global markets, where the products are already available in more than 50 countries and regions and reimbursed in more than 20 European countries, including the UK, France, Germany, Italy, the Netherlands and the Nordic countries.

The bottom line: - Medtrum used EDM HK 2026 to argue that automated insulin delivery is becoming easier to adopt, more relevant to real patients and dependent on strong support after launch.